Talis Biomedical Announces CEO Transition
August 30 2021 - 4:30PM
Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to
developing innovative molecular diagnostic tests for infectious
diseases at the point-of-care, today announced that effective
immediately Brian Coe has stepped down as President, CEO and
Director and will continue to work with the company as an advisor.
The company also announced that Kim Popovits has been appointed as
interim CEO and will lead the search efforts to hire the Company’s
next President and CEO.
Ms. Popovits is the former Chairman of the Board, President and
Chief Executive Officer of Genomic Health. Under her leadership
Genomic Health became the world’s leading provider of genomic-based
diagnostic tests that optimized the treatment of cancer, resulting
in an acquisition by Exact Sciences for $3B in 2019. Prior to
joining Genomic Health in 2002, Ms. Popovits held several senior
management roles at Genentech where she led the commercialization
of 14 new therapeutics over 15 years. In addition to Talis, she
serves on the boards of 10x Genomics and Kiniksa Pharmaceuticals,
Ltd. Ms. Popovits has been a member of the Board of Talis since
2020 and has stepped off in connection with her appointment as
interim CEO in order for the Company to remain in compliance with
requirements for Board independence.
“On behalf of the entire Company and Board of Directors, I would
like to thank Brian for his valuable contributions and years of
service to Talis. His extraordinary vision and commitment have put
us in a strong position,” said Felix Baker, Ph.D., chairman of the
board of Talis. “I also want to thank Kim for stepping in to lead
Talis at this time. Kim’s operational leadership and expertise in
building and scaling global organizations for growth is ideally
suited to lead Talis through this important period.”
“I look forward to the opportunity to work with the experienced
senior leadership team at Talis to scale our operational and
commercial capabilities while working with our Board to identify a
new CEO to lead the next phase of our growth,” said Kim Popovits,
interim CEO. “I also want to thank Brian for his many
contributions, and value his continued guidance as an advisor as we
advance our strategy to expand access to high quality molecular
diagnostics, addressing a significant and growing unmet need.”
About Talis BiomedicalTalis is dedicated to
transforming diagnostic testing by developing and commercializing
innovative products that are designed to enable accurate, low cost,
and rapid molecular testing for infectious diseases at the
point-of-care. The company is developing the Talis One, a compact,
sample-to-answer, cloud-enabled, molecular diagnostic platform. For
more information, visit talisbio.com.
Forward-Looking Statements
This press release may contain forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. Words such as "may," "might," "will," "should," "believe,"
"expect," "anticipate," "estimate," "continue," "predict,"
"forecast," "project," "plan," "intend" or similar expressions, or
other words that convey uncertainty of future events or outcomes
can be used to identify these forward-looking statements.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things: our plans to scale our
operational and commercial capabilities; our ability to identify
and hire a new CEO to lead the Company; and our ability to grow and
expand our business. These statements are not guarantees of future
performance and are subject to certain risks, uncertainties and
other factors that could cause actual results and events to differ
materially and adversely from those indicated by such
forward-looking statements including, among others: the impact to
our business of the ongoing COVID-19 pandemic, including any impact
on our ability to market our products, demand for our products due
to deferral of procedures using our products or disruption in our
supply chain, our ability to achieve or sustain profitability, our
ability to gain market acceptance for our products and to
accurately forecast and meet customer demand, our ability to
compete successfully, our ability to enhance our product offerings,
development and manufacturing problems, capacity constraints or
delays in production of our products, maintenance of coverage and
adequate reimbursement for procedures using our products, product
defects or failures. These and other risks and uncertainties are
described more fully in the "Risk Factors" section and elsewhere in
our filings with the Securities and Exchange Commission and
available at www.sec.gov, including in our Annual Report on Form
10-K and Quarterly Reports on Form 10-Q. Any forward-looking
statements that we make in this announcement speak only as of the
date of this press release, and Talis assumes no obligation to
updates forward-looking statements whether as a result of new
information, future events or otherwise after the date of this
press release, except as required under applicable law.
ContactMedia & InvestorsEmily
Faucetteefaucette@talisbio.com 415-595-9407
Talis Biomedical (NASDAQ:TLIS)
Historical Stock Chart
From Apr 2024 to May 2024
Talis Biomedical (NASDAQ:TLIS)
Historical Stock Chart
From May 2023 to May 2024